FDA clears IND application of GT307
“GT307 employs high-fidelity CRISPR/AaCas12MAX gene editing to knock out key immune regulatory genes, designed to address key bottlenecks of conventional TIL therapies, such as TIL exhaustion within the tumor microenvironment and insufficient persistence in vivo,” said Dr. Yarong Liu, CEO, Grit Biotechnologies. “This precise gene-editing strategy, combined with the extensive cell and gene therapy manufacturing experience of our partner uBriGene, allows us to advance next-generation TIL therapies efficiently and safely into the clinic.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.